If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
ARYA Sciences Acquisition III (ARYA)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
Duck Creek Technologies, Inc. (DCT)
Priced IPO
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
More companies

AnPac Bio-Medical Science (ANPC)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a biotechnology company focusing on early cancer screening and detection. They market and sell a multi-cancer screening and detection test that uses their innovative, patented cancer differentiation analysis, or CDA, technology and their proprietary cancer-detection device, or CDA device. In addition to early cancer screening and detection, their CDA technology has demonstrated potential to assist physicians in cancer diagnosis, prognosis and recurrence. Their CDA technology provides a comprehensive platform on which they have developed their cancer screening and detection test using their CDA technology, or CDA test, and their proprietary CDA device. Their CDA test can detect and assess an individual’s overall cancer risk with high accuracy, including early stage cancer. In addition, they also offer tests that combine their CDA test with auxiliary tests based on other cancer screening and detection technologies, such as biomarker-based tests, using their proprietary algorithm, which they refer to as combination tests. When they refer to their technology or tests as a “cancer screening and detection” technology or test in this prospectus, they refer to the detection and assessment of the risk of cancer occurrence, not to cancer diagnosis. Their CDA technology focuses on biophysical properties in human blood. Recent studies have shown that there is a correlation between certain biophysical properties, including acoustical, electrical, magnetic, nano-mechanical and optical properties, and cancer occurrence.
Chris Chang Yu Rain Yu Zhang
Employees Founded
101 2010


Address: 801 Bixing Street, Bihu County Lishui, Zhejiang Province 323006, People’s Republic of China

Telephone: +86-578-2051-6666

Web page:

IPO information

Expected Date 1/13/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $134.4
Revenues (MM) $1.6
Net Income (Loss) (MM) $-11.3


What do you think will happen with the ANPC share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 1.7
Shares Revised (MM) 1.3
Expected offer amount (MM) $21.7
Realized offer amount(MM) $15.6
WestPark Capital

Sector: Healthcare

Tweets about $ANPC

Tweets volume:

RT volume:


Google Trends Stats